Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

309.06USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$309.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
491,995
52-wk High
$348.65
52-wk Low
$244.31

Select another date:

Tue, Nov 21 2017

BRIEF-Biogen appoints Jeff Capello as executive vice president and chief financial officer

* Appoints Jeff Capello as executive vice president and chief financial officer

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

BRIEF-Biogen presents new data from long-term extension of phase 1B study

* Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab

UPDATE 2-Biogen beats profit estimates, but sales of Spinraza disappoint

Oct 24 Biogen Inc beat Wall Street estimates for third-quarter profit as it curbed spending, but U.S. sales of Spinraza, a potential future blockbuster drug, were disappointing and sent the U.S. drugmaker's shares nearly 3 percent lower on Tuesday.

BRIEF-Biogen Q3 earnings per share $5.79

* Biogen Inc - ‍company restructures collaboration arrangements with eisai and neurimmune to improve long-term value of aducanumab​

Biogen posts 18.7 pct jump in quarterly profit

Oct 24 U.S. drugmaker Biogen Inc on Tuesday reported an 18.7 percent rise in quarterly profit, driven by strong demand for its recently approved spinal muscular atrophy drug, Spinraza.

BRIEF-Biogen increases profit potential on investigational Alzheimer’S disease treatment

* Biogen increases profit potential on investigational Alzheimer’S disease treatment Aducanumab through amended agreement with Neurimmune Holding AG

BRIEF-Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

* Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

BRIEF-Biogen updates on new data on treatment with Spinraza

* Presented new data showing earlier initiation of treatment with Spinraza may improve motor function outcomes in infants with spinal muscular atrophy

BRIEF-Biogen appoints Sanjay Jariwala as SVP

* Biogen appoints Sanjay Jariwala as SVP, worldwide medical Source text for Eikon: Further company coverage:

Select another date: